

Table 2. SURVIVAL FIGURES OF EXTRACRANIAL GCTs										
SURVIVAL OUTCOMES OF Malignant GCTs (n-254)						SURVIVAL OUTCOMES OF All GCTs (n-297)				
Variable	n	5 yr EFS		5 yr OS		n	5 yr EFS		5 yr OS	
		%	p-value	%	p-value		%	p-value	%	p-value
	254	72.50	-	82.70	-	297	79.30	-	84.40	-
AGE										
<3 years	110	69.70		81.10		135	77.70		82.90	
3-11 years	59	68.70	0.724	81.00	0.842	69	76.00	0.802	83.80	0.872
>11 years	85	78.70		85.80		93	83.80		87.00	
GENDER										
Male	92	67.50	0.347	83.00	0.867	109	79.00	0.754	84.60	0.886
Female	162	75.40		82.60		188	79.50		84.30	
Primary site										
Gonadal	162	79.60	0.002	90.60	<0.001	180	85.10	0.006	91.50	<0.001
Extragonadal	92	60.30		69.30		117	71.80		73.70	
STAGE										
Stage I	23	78.00	0.020	100.00	<0.001	60	85.40	0.001	98.10	<0.001
Stage II	30	79.70		100.00		31	93.10		100	
Stage III	126	77.70		83.30		131	81.80		83.20	
Stage IV	75	59.20		68.50		75	64.40		68.70	
TMH RISK										
Low Risk	23	78.00	0.042	100.00	<0.001	60	85.40	0.002	98.10	<0.001
Intermediate Risk	122	79.70		90.80		125	86.9		91.00	
High Risk	109	63.4		70.20		112	68.10		70.30	
AFP										
<1000	21	78.90	0.753	84.20	0.867	20	78.90	0.753	84.20	0.867
≥1000	129	78.40		84.40		129	78.40		84.40	
MaGIC RISK (n-192)										
Standard Risk 1	136	73.90	0.623	78.20	0.191					
Standard Risk 2	31	87.10		90.30						
Poor Risk	25	72.00		72.6						
Chemo regimen (n-231)										
Cisplatin (PEb)	181	79.30	0.054	83.30	0.024					
Carboplatin (JEb)	27	80.50		80.10						
Hybrid (PEb+JEb)	23	60.90		64.00						